Results 221 to 230 of about 22,609,350 (346)

UBE2C‐Mediated CD147‐CTLA‐4 Axis Promotes T Cell Exhaustion and Immunosuppressive Microenvironment in Bladder Cancer

Cancer Science, EarlyView.
UBE2C upregulates cellular CD147 and enhances its release into the tumor microenvironment both as soluble CD147 (sCD147) and packaged within tumor‐derived exosomes. These CD147‐bearing signals induce T‐cell exhaustion, marked by elevated CTLA‐4 expression and reduced secretion of effector cytokines (IFN‐γ, TNF‐α, TGF‐β), ultimately diminishing CD8+ T ...
Xuwei Hong, Ting Hong, Xinyu Liu, Peixiu Yao, Weiqiang Lin, Guoyuan Liu, Huihong Guan, Yonghai Zhang   +7 more
wiley   +1 more source

Mechanistic drivers of PD-L1/CTLA-4 checkpoint inhibitor-associated immune toxicity and systemic organ injury. [PDF]

Front Oncol
Chen J, Zhang L, Gao M, Min S.
europepmc   +1 more source

FDX1 Depletion Activates CD8+ T Cell Antitumor Immunity by Promoting DMBT1 Secretion in Cuproptosis of Colorectal Cancer

Cancer Science, EarlyView.
Elesclomol‐induced cuproptosis potently activates both innate and adaptive antitumor immunity, especially CD8+ T cell immunity. FDX1 serves as a central regulator of CD8+ T cell functionality through DMBT1 downregulation during cuproptosis in colorectal cancer.
Jieqiong Wu, Zaixi Lian, Mingzhou Li, Xingtu Qin, Xiaoyu Lei, Lihua Yang, Lin Bing, Qiuyue Li, Lingyan Zhou, Zhiyang Ma, Xuemei Xu, Jinghao Huang, Zilong Chen, Lijie Chen, Lingjie Zhang, Zhiyuan Xiao, Xiangyu Jian, Xiaoqin Zhang, Yanqing Ding, Yaping Ye, Li Liang, Hongli Jiao, Shuyang Wang   +22 more
wiley   +1 more source

From Cold to Hot: Nanozyme‐Based Strategies for Reprogramming the Tumour Immunoenvironment

Cell Proliferation, EarlyView.
Nanozymes, with multi‐enzyme catalytic activities, reprogram the immunosuppressive tumour microenvironment by inducing immunogenic cell death, relieving hypoxia, and depleting antioxidants, effectively converting immunologically “cold” tumours into “hot” ones to boost cancer immunotherapy efficacy.
Yue Wang, Miao Xu, Yongshun Wang, Xuan Lin, Qiang Zhang, Xiaoning Lin, Xin Wu, Cheng Zhang, Wenhua Huang, Jianlin Shen   +9 more
wiley   +1 more source

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

Proceedings of the National Academy of Sciences of the United States of America, 2010
M. Curran, Welby Montalvo, H. Yagita, J. Allison   +3 more
semanticscholar   +1 more source

Role of CTLA-4 blockade and dacarbazine therapy following anti-PD-1 resistance in melanoma. [PDF]

Discov Oncol
Urbonas V, Dulskas A.
europepmc   +1 more source

From Tumour to Bloodstream: Advancing PD‐L1 Testing With Liquid Biopsies in Non‐Small Cell Lung Cancer

Cytopathology, EarlyView.
This review explores liquid biopsy as a complementary approach to tissue‐based PD‐L1 assessment in advanced NSCLC treated with immune checkpoint inhibitors. Focusing on circulating tumour cells, extracellular vesicles, and circulating tumour DNA, it summarises current evidence, technical challenges, and future perspectives for personalised ...
R. Leporati, V. Callegari, A. Ancora, M. Palmieri, B. Riccò, E. Cabitza, L. Trudu, K. Di Emidio, C. Chiavelli, A. Eccher, I. Mastrolia, V. Catani, S. Bettelli, G. Guaitoli, M. Dominici, F. Bertolini   +15 more
wiley   +1 more source

Incidence, severity and potential pathomechanism of immune‐related pruritus in melanoma patients undergoing immune checkpoint inhibitor therapy

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Pruritus is a frequent cutaneous immune‐related adverse event (irAE) associated with immune checkpoint inhibitors (ICI), impacting patients' quality of life. This study investigates the incidence, severity and management of pruritus in melanoma patients treated with ICI.
Andrea Roggo, Nikolina Ivanovic, Patrick Turko, Lukas Kraehenbuehl, Mitchell Levesque, Reinhard Dummer, Barbara Meier‐Schiesser   +6 more
wiley   +1 more source

Umbrella Systematic Review of the Efficacy and Safety of PD-1 Inhibitors Combined with CTLA-4 Inhibitors in the Treatment of Melanoma. [PDF]

Int J Mol Sci
Zhou Z, Zhu C, Yang Q, Ji C, Ma L, Wang F.   +5 more
europepmc   +1 more source

CTLA-4 Antisense Oligonucleotide Contributes to Enhanced Immunogenicity of an Adjuvanted Recombinant <i>Sporothrix</i> spp. Enolase Antigen. [PDF]

Vaccines (Basel)
Momente GJ, Portuondo DL, Deus AF, Curti Gonçalves MR, Piccineli FL, de Oliveira Campos TPC, Téllez-Martínez D, Carlos IZ, Batista-Duharte A.   +8 more
europepmc   +1 more source